Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug

Seeking AlphaApr 23 22:29

Avidity Biosciences(RNA.US) Director Sells US$114.12K in Common Stock

$Avidity Biosciences(RNA.US)$ Director LEVIN ARTHUR A sold 5,000 shares of common stock on Apr 19, 2024 at an average price of $22.8246 for a total value of $114.12K.Source: Announcement What is state

Futu NewsApr 23 06:10

FYBR, BCRX and SABR Are Among After Hour Movers

Seeking AlphaApr 19 04:56

Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target

Needham analyst Joseph Stringer reiterates Avidity Biosciences with a Buy and maintains $35 price target.

Analyst UpgradesApr 11 19:23

Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)

TipRanksApr 11 18:40

Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing

Arthur A Levin, Director, on April 03, 2024, sold 20,000 shares in Avidity Biosciences (RNA) for $542,214. Following the Form 4 filing with the SEC, Levin has control over a total of 268,702 shares of

MT NewswiresApr 4 22:10